Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Naho, Kagiyama"'
Autor:
Taisuke Isono, Naho Kagiyama, Shun Shibata, Hitomi Nakajima, Yuma Matsui, Kenji Takano, Takashi Nishida, Chiaki Hosoda, Eriko Kawate, Yoichi Kobayashi, Takashi Ishiguro, Yotaro Takaku, Kazuyoshi Kurashima, Tsutomu Yanagisawa, Noboru Takayanagi
Publikováno v:
Thoracic Cancer, Vol 12, Iss 9, Pp 1387-1397 (2021)
Abstract Background Although clinical trials have investigated the addition of pembrolizumab to chemotherapy for non‐small cell lung cancer, none have investigated the addition of chemotherapy to pembrolizumab. Methods We conducted a retrospective
Externí odkaz:
https://doaj.org/article/5ef23fc521cd4c0baccdca9b0b6b437b
Autor:
Shuko Hirota, Yoichi Kobayashi, Takashi Ishiguro, Takashi Nishida, Naho Kagiyama, Yoshihiko Shimizu, Noboru Takayanagi
Publikováno v:
Respiratory Medicine Case Reports, Vol 26, Iss , Pp 59-62 (2019)
A 56-year-old woman was referred to our hospital for recurrent asthma of 20 years duration. She was diagnosed as having allergic bronchopulmonary aspergillosis on the basis of clinical symptoms, peripheral blood eosinophilia, elevated total serum imm
Externí odkaz:
https://doaj.org/article/72a8340d77db4a2cb9218032573e1bd3
Autor:
Takashi Ishiguro, Kenji Takano, Naho Kagiyama, Chiaki Hosoda, Yoichi Kobayashi, Yotaro Takaku, Naomi Takata, Miyuki Ueda, Yasuhiro Morimoto, Keisuke Kasuga, Ryota Ozawa, Taisuke Isono, Takashi Nishida, Eriko Kawate, Yasuhito Kobayashi, Yoshihiko Shimizu, Kazuyoshi Kurashima, Tsutomu Yanagisawa, Noboru Takayanagi
Publikováno v:
Respiratory Medicine Case Reports, Vol 31, Iss , Pp 101207- (2020)
Objective: To clarify what future problems must be resolved and how clinical findings of SARS-CoV-2 infection differ from those of cHCoV infection. Methods: Patients and Methods Clinical characteristics of 14 patients with laboratory-confirmed Corona
Externí odkaz:
https://doaj.org/article/0223f87e617a4ad08b1642dd7d72ffb5
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0230746 (2020)
BACKGROUND:The incidence and etiologies of chronic pulmonary infection (CPI) in patients with idiopathic pulmonary fibrosis (IPF) have been poorly investigated. METHODS:We conducted a retrospective study of 659 patients with IPF to assess the inciden
Externí odkaz:
https://doaj.org/article/75ea49a9b5a045f18ab629fb53c7c9c8
Autor:
Eisuke Kato, Noboru Takayanagi, Yotaro Takaku, Naho Kagiyama, Tetsu Kanauchi, Takashi Ishiguro, Yutaka Sugita
Publikováno v:
ERJ Open Research, Vol 4, Iss 1 (2018)
The incidence and risk factors of lung cancer in patients with idiopathic pulmonary fibrosis (IPF) have been poorly investigated. We conducted a retrospective study of 632 patients with IPF to assess the incidence and risk factors of lung cancer deve
Externí odkaz:
https://doaj.org/article/d2582073e96b4f5f8b5e145746538457
Autor:
Aya Wakabayashi, Takashi Ishiguro, Yotaro Takaku, Yosuke Miyahara, Naho Kagiyama, Noboru Takayanagi
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201799 (2018)
BACKGROUND:To elucidate the characteristics of pneumonia in rheumatoid arthritis (RA) patients and to assess whether pneumonia in RA patients differs from that in non-RA patients. METHODS:We retrospectively divided pneumonia patients into two groups,
Externí odkaz:
https://doaj.org/article/f69eaf855bf6430898b27a8dd931cf41
Autor:
Takashi Ishiguro, Naho Kagiyama, Noboru Takayanagi, Yoichi Kobayashi, Yoshihiko Shimizu, Yotaro Takaku
Publikováno v:
Internal Medicine
Fibrosing mediastinitis (FM) is a rare fibroinflammatory disease of the mediastinum with an etiology and clinical features that vary by world region. The characteristics of FM in Japan are still unknown. We herein report two Japanese patients with FM
Autor:
Taisuke Isono, Jiro Hasemi, Airi Hasegawa, Takashi Nishida, Chiaki Hosoda, Eriko Kawate, Yoichi Kobayashi, Takashi Ishiguro, Naho Kagiyama, Kazuyoshi Kurashima, Tsutomu Yanagisawa, Noboru Takayanagi
Purpose No clinical trial has compared osimertinib with afatinib. We reviewed clinical data of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) to identify predictive factors for clinical outcome of fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::502e06f82c943528b7abf7dc0e56443e
https://doi.org/10.21203/rs.3.rs-2128762/v1
https://doi.org/10.21203/rs.3.rs-2128762/v1
Autor:
Satoshi Iwata, Naoki Miyao, Takashi Naka, Takatomo Hirouchi, Atsushi Nakagawa, Yoshihiko Matsumoto, Yutaka Tokue, Jiro Terada, Kenji Tsushima, Kazutoshi Hiyama, Eri Hagiwara, Daiki Kanou, Shuichi Kawano, Tsutomu Sakurai, Yuko Komase, Yuji Hirai, Masahiro Shinoda, Shinichiro Ota, Mikio Takamori, Yoshitaka Yamazaki, Mitsunaga Iwata, Shingo Tanaka, Ichiro Kawada, Sho Fujiwara, Norihito Tarumoto, Kenya Ie, Shinichi Antoku, Naho Kagiyama, Megumi Shimada, Yujiro Uchida, Hiroyuki Kunishima, Osamu Kobayashi, Kazumasa Harada, Takeshi Saraya, Yasuhiro Gon, Yoshihiko Ogawa, Takashi Ogura, Masaharu Shinkai, Hidefumi Koh
Publikováno v:
Infectious Diseases and Therapy
Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded RNA virus. Favipiravir is an orally administrable antiviral drug whose mechanism of action i
Autor:
Tsutomu Yanagisawa, Naho Kagiyama, Kazuyoshi Kurashima, Kenji Takano, Takashi Nishida, Eriko Kawate, Taisuke Isono, Yoichi Kobayashi, Youtaro Takaku, Noboru Takayanagi, Chiaki Hosoda, Takashi Ishiguro
Publikováno v:
Thoracic Cancer
Background Non‐small cell lung cancer (NSCLC) patients with pre‐existing respiratory diseases have been excluded in clinical trials of immune checkpoint inhibitor (ICI) therapy, and it is unknown whether the same degree of response can be expecte